Amsety Announces ACRE, an AI-Based Solution to Improve Patient Enrollment in Clinical Trials for Liver Disease
CARLSBAD, Calif., Nov. 7, 2023 /PRNewswire/ -- Amsety, a liver health solutions start-up announced the release of its new artificial intelligence-driven Amsety Clinical Recruitment Engine ("ACRE"). ACRE combines decisional AI and messaging tools with a proprietary, self-selected database of over half a million users to help efficiently reach and effectively communicate with liver patients. As proven in the first pilot projects, ACRE is an effective way to engage candidates for clinical trials and educational outreach in the context of liver health and other metabolic diseases.
- CARLSBAD, Calif., Nov. 7, 2023 /PRNewswire/ -- Amsety, a liver health solutions start-up announced the release of its new artificial intelligence-driven Amsety Clinical Recruitment Engine ("ACRE").
- As proven in the first pilot projects, ACRE is an effective way to engage candidates for clinical trials and educational outreach in the context of liver health and other metabolic diseases.
- Millions of Americans with Liver Disease, Yet Clinical Trials Are Struggling with Patient Recruitment
Despite over 100 million Americans being affected by liver disease, clinical trial recruiters experience a shortage of eligible liver patients to enroll in their studies resulting in high recruitment failure rate, prolonged clinical studies, and delay in drug development. - ACRE offers a novel method to activate patients more rapidly and efficiently for recruitment into clinical trials and disease education.